painfocus™ uses advanced machine learning that combines multiple physiology biomarkers captured using wearable devices to calculate the presence and severity of pain
Leveraging on Biofourmis’ biovitals™ analytics engine, painfocus™ uses advanced machine learning that combines multiple physiology biomarkers captured using wearable devices to calculate the presence and severity of pain.
The app can capture, monitor and analyse data generated by patients in an inpatient or outpatient setting, and share with caregivers an accurate picture of health including level of pain, quality of life and general physiology in real-time via a web-based dashboard.
It also enables digital patient-caregiver communication, which is particularly significant for patients who don’t have the ability to verbally explain how they’re suffering.
painfocus™ has been tested in an early feasibility study conducted in multiple hospitals in South Africa from January to May 2018 that continuously monitored the physiology of knee arthroplasty patients using Everion® physiology monitor. The study found significant correlations between patient-reported pain scores and the results calculated by painfocus™ in an ambulatory, real-world setting.
Mundipharma’s latest digital healthcare solution was developed and tested in partnership with leading digital health technology company Biofourmis, which specializes in augmenting personalized care with digital therapeutics.
painfocus™ will further be evaluated in an investigator-initiated study in multiple public hospitals in Singapore, on how this solution can augment clinical care for patients in treatment. The study is being funded by Mundipharma.
Mundipharma has been early adopters of innovative technology including, virtual reality, augmented reality and gamification. These initiatives have been primarily focused on medical education for both doctors and patients and have been developed in response to ongoing unmet needs.